No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PGEN Precigen
- 1.320
- +0.010+0.76%
Close Apr 18 16:00 ET
- 1.340
- +0.020+1.52%
Post 19:53 ET
328.57MMarket Cap-3384P/E (TTM)
1.355High1.280Low1.12MVolume1.300Open1.310Pre Close1.48MTurnover0.91%Turnover RatioLossP/E (Static)248.92MShares1.88052wk High2.77P/B161.67MFloat Cap0.83552wk Low--Dividend TTM122.48MShs Float11.100Historical High--Div YieldTTM5.73%Amplitude0.805Historical Low1.319Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HP
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
Precigen Cut to Underweight From Neutral by JP Morgan
Precigen Cut to Underweight From Neutral by JP Morgan
J.P. Morgan Cuts Precigen to Underweight, Cites Burn Rate
Precigen's Financial Tightrope: Balancing R&D Investment and Funding Challenges Amid Economic Headwinds
Precigen Price Target Maintained With a $14.00/Share by JMP Securities
Precigen Price Target Maintained With a $14.00/Share by JMP Securities
Comments
The company's share price decline mirrors its poor fundamental performance. The recent loss isn't as severe as the 13% annual loss investors endured over the past five years. Key metrics need improvement to generate enthusiasm.
Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss
News
$Precigen(PGEN.US$Moomoo 24/7· 3 mins ago
Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission
Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission
Precigen's declining revenue may necessitate additional funding, potentially diluting existing shareholder stakes. Despite a decrease in cash burn, falling revenue raises apprehension. Investors are urged to fully comprehend business risks prior to investing.
Coming in hot
$Precigen(PGEN.US$ will be releasing their earnings report on Monday. Just like in the past, they're well in tune with beating the projected -0.1 EPS estimate. If you aren't already loaded up, now is the time. If you dont already know, last quarter, the company beat EPS by $0.10, which was followed by a 21.09% increase in the share price the next day.
2
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg